The Effect of SGLT2 Inhibitors on the Development of Contrast-Induced Nephropathy in Diabetic Patients with Non-ST Segment Elevation Myocardial Infarction

Basit Öğe Kaydı
dc.authoridÖzkan, Uğur/0000-0002-7552-7654
dc.authoridGURDOGAN, Muhammet/0000-0001-5650-9066
dc.authorwosidÖzkan, Uğur/ACR-6091-2022
dc.contributor.authorOzkan, Ugur
dc.contributor.authorGurdogan, Muhammet
dc.date.accessioned2024-06-12T10:58:24Z
dc.date.available2024-06-12T10:58:24Z
dc.date.issued2023
dc.departmentTrakya Üniversitesien_US
dc.description.abstractBackground and Objectives: Percutaneous procedures using contrast agents are modern diagnosis and treatment methods for cardiovascular diseases. Contrast use may cause nephropathy, especially in diabetic patients. SGLT2 inhibitors have strong cardioprotective and renal protective effects. In our study, we investigated the effectiveness of this drug group in preventing the development of Contrast-Induced Nephropathy (CIN). Materials and Methods: The results of 312 diabetic patients who underwent CAG were analyzed. The study group included 104 DM patients using SGLT2 and the control group did not use SGLT2. These groups were compared with each other in terms of clinical, demographic, and laboratory parameters. Results: The groups were similar characteristics. However, post-CAG creatinine values compared with before the procedure, the development of CIN was observed to be significantly less in the group using SGLT2 inhibitor (p = 0.03). When the results of the multivariate analysis were examined, it was seen that the use of SGLT2 inhibitors significantly reduced the risk of CIN (odds ratio (OR): 0.41, 95% confidence interval (CI): 0,142-0.966, p = 0.004). Conclusions: Our study showed that SGLT2 inhibitors may be protective against the development of CIN, especially in patients with comorbid conditions such as diabetes.en_US
dc.identifier.doi10.3390/medicina59030505
dc.identifier.issn1010-660X
dc.identifier.issn1648-9144
dc.identifier.issue3en_US
dc.identifier.pmid36984506en_US
dc.identifier.scopus2-s2.0-85151110689en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.urihttps://doi.org/10.3390/medicina59030505
dc.identifier.urihttps://hdl.handle.net/20.500.14551/20060
dc.identifier.volume59en_US
dc.identifier.wosWOS:000958884500001en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherMdpien_US
dc.relation.ispartofMedicina-Lithuaniaen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectContrast Induced Nephropathyen_US
dc.subjectCoronary Angiographyen_US
dc.subjectPercutaneous Coronary Interventionsen_US
dc.subjectSGLT2 Inhibiorsen_US
dc.subjectRisk-Factorsen_US
dc.subjectGuidelinesen_US
dc.subjectTherapyen_US
dc.subjectDiseaseen_US
dc.subjectInjuryen_US
dc.subjectMediaen_US
dc.titleThe Effect of SGLT2 Inhibitors on the Development of Contrast-Induced Nephropathy in Diabetic Patients with Non-ST Segment Elevation Myocardial Infarctionen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu